A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT

Inclusion Criteria: * Previously untreated patients with newly diagnosed peripheral T-cell lymphoma of all stages. However, patients with nodal stage IA non-bulky disease (\<10cm) can be treated individually at the discretion of the responsible physician. * Following histologic subtypes (WHO classification) are eligible for inclusion in the study: Peripheral T-cell lymphomas, unspecified Angioimmunoblastic T-cell lymphoma NK/T nasal-type T-cell lymphoma Enteropathy-type T-cell lymphoma Primary systemic, alk-negative anaplastic large cell lymphoma (T-or null phenotype) Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma NB: Patients should not enter the treatment program before confirmation of the histo-pathological diagnosis by the referral center pathologist * Age 18-60 years. Patients in the age range 61-67 years may be included in this protocol at discretion of the treating physician. * formed consent based on oral and written patient information (Appendix I) Exclusion Criteria: * Primary cutaneous T-or null-cell anaplastic large-cell lymphoma * Alk-positive, primary systemic T-or null-cell anaplastic large-cell lymphoma * WHO Performance Status grade 4 (Appendix II) * Patients with severe cardiac (i.e. severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45%), pulmonary, neurologic, psychiatric, renal, hepatic or metabolic disease. * Pregnancy. N.B: Women of childbearing potential should be strongly advised to apply appropriate contraceptive precautions during the entire treatment period. * Patients with concomitant malignancies except for non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. * Patients with seropositivity for the human immunodeficiency virus. * Patients with other active and therapeutically uncontrolled infection. * Psychological, familial, social or other condition/-s potentially hampering compliance and follow-up.